SIRPA and neoplasm: After discovering the CD47-SIRPα recognition mechanism of tumor cells and macrophages, researchers used an anti-CD47 monoclonal antibody to carry out in vivo experiments on tumor-bearing mice, and found the antibody can block the CD47-SIRPα pathway to interdict the signal of anti-phagocytosis (Figure 3B).